PE06762015A1 - Pharmaceutical composition containing an agonist of the receptor s1p and sugar alcohol - Google Patents

Pharmaceutical composition containing an agonist of the receptor s1p and sugar alcohol

Info

Publication number
PE06762015A1
PE06762015A1 PE2015000303A PE0003032015A PE06762015A1 PE 06762015 A1 PE06762015 A1 PE 06762015A1 PE 2015000303 A PE2015000303 A PE 2015000303A PE 0003032015 A PE0003032015 A PE 0003032015A PE 06762015 A1 PE06762015 A1 PE 06762015A1
Authority
PE
Peru
Prior art keywords
agonist
pharmaceutical composition
composition containing
sugar alcohol
receptor s1p
Prior art date
Application number
PE2015000303A
Other languages
Spanish (es)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US46121503P priority Critical
Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE06762015(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of PE06762015A1 publication Critical patent/PE06762015A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Abstract

La invencion describe una composicion farmaceutica solida en la forma de granulos, pellets, una tableta o capsula, que comprende: (a) un agonista del receptor S1P; The invention describes a solid pharmaceutical composition in the form of granules, pellets, a tablet or capsule, comprising: (a) a S1P receptor agonist; y (b) manitol; and (b) mannitol; en donde el agonista del receptor de S1P es 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol o una sal farmaceutica del mismo wherein the agonist S1P receptor is 2-amino-2- [2- (4-octylphenyl) ethyl] propane-1,3-diol or a pharmaceutical salt the same
PE2015000303A 2003-04-08 2004-04-06 Pharmaceutical composition containing an agonist of the receptor s1p and sugar alcohol PE06762015A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US46121503P true 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
PE06762015A1 true PE06762015A1 (en) 2015-05-17

Family

ID=32326722

Family Applications (5)

Application Number Title Priority Date Filing Date
PE2013000382A PE13522013A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing an agonist of the receptor s1p and sugar alcohol
PE2012002027A PE02002013A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing an agonist of the receptor s1p and sugar alcohol
PE2015000303A PE06762015A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing an agonist of the receptor s1p and sugar alcohol
PE2008001684A PE07432009A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing a S1P receptor agonist and the sugar alcohol
PE2004000355A PE03962005A1 (en) 2003-04-08 2004-04-06 Solid pharmaceutical composition comprising a S1P receptor agonist and the sugar alcohol

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PE2013000382A PE13522013A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing an agonist of the receptor s1p and sugar alcohol
PE2012002027A PE02002013A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing an agonist of the receptor s1p and sugar alcohol

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2008001684A PE07432009A1 (en) 2003-04-08 2004-04-06 Pharmaceutical composition containing a S1P receptor agonist and the sugar alcohol
PE2004000355A PE03962005A1 (en) 2003-04-08 2004-04-06 Solid pharmaceutical composition comprising a S1P receptor agonist and the sugar alcohol

Country Status (43)

Country Link
US (9) US20060275357A1 (en)
EP (5) EP2319502A1 (en)
JP (3) JP5495467B2 (en)
KR (3) KR20110005320A (en)
CN (2) CN101797241B (en)
AR (3) AR043987A1 (en)
AT (3) AT501681B1 (en)
AU (1) AU2004228929B2 (en)
BE (1) BE1015972A5 (en)
BR (1) BRPI0409250A (en)
CA (2) CA2707750A1 (en)
CL (2) CL2004000745A1 (en)
CY (2) CY1110260T1 (en)
DE (4) DE202004021680U1 (en)
DK (2) DK1613288T3 (en)
EC (1) ECSP056090A (en)
ES (3) ES2556947T3 (en)
FR (1) FR2854073B1 (en)
GB (1) GB2400318B (en)
GR (1) GR1005052B (en)
HK (3) HK1071685A1 (en)
HR (3) HRP20050886B1 (en)
HU (2) HUE028247T2 (en)
IE (1) IE20040246A1 (en)
IL (3) IL170888A (en)
IS (2) IS2682B (en)
IT (1) ITMI20040682A1 (en)
LU (1) LU91867I9 (en)
MA (1) MA27729A1 (en)
MX (1) MXPA05010860A (en)
MY (1) MY141249A (en)
NO (4) NO329332B1 (en)
NZ (3) NZ542622A (en)
PE (5) PE13522013A1 (en)
PL (2) PL1613288T3 (en)
PT (1) PT1613288E (en)
RU (5) RU2358716C2 (en)
SG (1) SG175449A1 (en)
SI (2) SI2316431T1 (en)
TN (1) TNSN05256A1 (en)
TW (1) TWI332847B (en)
WO (1) WO2004089341A1 (en)
ZA (1) ZA200507394B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1773307E (en) * 2004-07-30 2015-01-14 Novartis Ag Compound formulations of 2-amino-1,3-propanediol compounds
CN1891212B (en) 2005-07-07 2010-10-13 马启明 Oral preparation and its preparing method
WO2007028821A2 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
SI2623113T1 (en) 2005-11-09 2017-08-31 Onyx Therapeutics, Inc. Compound for enzyme inhibition
TWI389683B (en) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP2484688B1 (en) 2006-06-19 2016-06-08 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
LT3103448T (en) * 2006-09-26 2019-10-10 Novartis Ag Pharmaceutical compositions comprising an s1p modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
AU2008241982B2 (en) 2007-03-29 2013-02-21 Daiichi Sankyo Company, Limited Pharmaceutical composition
MY166950A (en) 2007-10-04 2018-07-25 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EP3120833A1 (en) * 2007-10-12 2017-01-25 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (en) * 2008-01-11 2014-07-02 日医工株式会社 Oral dosage formulation containing sarpogrelate hydrochloride with excellent stability in an unwrapped state
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
EP2278960B2 (en) 2008-03-17 2019-11-13 Actelion Pharmaceuticals Ltd. Dosing regimen for a selective sip1 receptor agonist
MX2010014209A (en) * 2008-06-20 2011-02-21 Merck Patent Gmbh Directly injection moldable and rapidly disintegrating tablet matrix.
KR20180017232A (en) 2008-06-20 2018-02-20 노파르티스 아게 Paediatric compositions for treating multiple sclerosis
WO2010025796A1 (en) * 2008-09-04 2010-03-11 Cargill Incorporated Tabletting of ervthritol
EA201690276A1 (en) 2008-10-21 2016-10-31 Оникс Терапьютикс, Инк. Combined therapy with the application of peptide epoxyketones
PT2356090T (en) * 2008-11-11 2017-10-16 Novartis Ag Crystalline forms of fingolimod hcl
AU2013100532B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
BRPI0921533A2 (en) 2008-11-11 2016-01-12 Novartis Ag organic compost
KR101463653B1 (en) 2008-12-17 2014-11-19 다이이찌 산쿄 가부시키가이샤 Method for producing diamine derivative
WO2010082531A1 (en) 2009-01-13 2010-07-22 第一三共株式会社 Active blood coagulation factor inhibitor
CN102348688B (en) 2009-03-10 2014-07-09 第一三共株式会社 Process for producing diamine derivative
ES2542237T3 (en) 2009-03-13 2015-08-03 Daiichi Sankyo Company, Limited Production process of an optically active diamine derivative
TWI504598B (en) 2009-03-20 2015-10-21 Onyx Therapeutics Inc Crystalline tripeptide epoxy ketone protease inhibitors
EP2444087B1 (en) * 2009-06-18 2016-09-07 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved solubility
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
SG183843A1 (en) 2010-03-01 2012-10-30 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
WO2011115067A1 (en) 2010-03-19 2011-09-22 第一三共株式会社 Method for improving dissolvability of anticoagulant
CA2793413C (en) 2010-03-19 2015-11-24 Daiichi Sankyo Company, Limited Crystal form of edoxaban tosylate monohydrate and method of producing same
EA201291095A1 (en) * 2010-04-22 2013-04-30 Рациофарм Гмбх Method for obtaining oral medical form containing fingolimod
BR112013000085A2 (en) 2010-07-02 2016-05-10 Daiichi Sankyo Co Ltd process for preparing optically active diamine-derived salt
WO2012070059A1 (en) 2010-11-25 2012-05-31 Shilpa Medicare Limited Fingolimod polymorphs and their processes
JO3177B1 (en) 2011-04-01 2018-03-08 Novartis Ag Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
EA028950B1 (en) 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Process for preparing pharmaceutical compositions comprising fingolimod
ES2673182T3 (en) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Pharmaceutical composition containing a diamine derivative
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (en) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Pharmaceutical composition of s1p receptor agonist for treatment of demyelinating diseases (versions) and method of its obtaining
RU2506949C1 (en) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Pharmaceutical composition of sip receptor agonist for treating demyeliniating diseases
UY34897A (en) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Prodrugs peptidic protease inhibitors expoxy ketone
RU2496486C1 (en) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Pharmaceutical composition exhibiting improved flowability, drug preparation, method for preparing and using
CN109432073A (en) * 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Purposes of the MGBG in the drug that preparation treats or prevents progressive MS and its progress
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
MX2015015681A (en) * 2013-05-13 2016-03-15 Synthon Bv Pharmaceutical composition comprising fingolimod.
US20160128951A1 (en) * 2013-07-29 2016-05-12 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (en) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Pharmaceutical composition of s1p receptor agonist for treating demyeliniating diseases
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RU2577230C1 (en) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Method of producing capsules of fingolimod hydrochloride
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (en) * 1976-07-12 1978-01-16 Akzo Nv A process for the preparation of novel peptides and peptide derivatives and the use thereof.
US4110332A (en) 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (en) * 1990-11-29 1998-12-24 田辺製薬株式会社 Long-term stable oral pharmaceutical formulations
EP0627406B1 (en) * 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
DK0778263T3 (en) 1994-08-22 2002-04-22 Mitsubishi Pharma Corp Benzene compounds and the pharmaceutical use of these
WO1997024112A1 (en) 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (en) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp Medicinal composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
EP0990440B1 (en) * 1997-02-27 2008-10-29 Novartis AG Pharmaceutical composition comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, a lecithin and a saccharide
EP1002792B1 (en) * 1997-04-04 2004-07-14 Mitsubishi Pharma Corporation 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same
JPH1180026A (en) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd New immunosuppressant, its use and its identification
JPH11209277A (en) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd Pharmaceutical composition
JP3545595B2 (en) 1998-04-01 2004-07-21 花王株式会社 The process of glycosphingolipid
JP4627356B2 (en) 1999-06-30 2011-02-09 松森  昭 Drugs for preventing or treating viral myocarditis
EP1195165A4 (en) 1999-07-12 2005-08-10 Ono Pharmaceutical Co Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate
SK152003A3 (en) 2000-07-13 2004-07-07 Sankyo Co Amino alcohol derivatives
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
CA2442178A1 (en) 2001-03-26 2002-10-03 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (en) 2001-04-20 2002-10-31 Sankyo Co Ltd Benzothiophene derivative
WO2003020313A1 (en) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
AU2002332289B2 (en) 2001-09-27 2007-05-10 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
WO2003062392A2 (en) 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
AT448193T (en) 2002-01-18 2009-11-15 Merck & Co Inc ßN- (BENZYL) AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE AND TETRAZOLE AS EDG RECEPTOR AGONISTENS
DE602005027074D1 (en) * 2004-07-16 2011-05-05 Kyorin Seiyaku Kk Method for effectively applying a medicament and method for preventing side effects

Also Published As

Publication number Publication date
IL197578A (en) 2015-10-29
PT1613288E (en) 2009-02-25
RU2358716C2 (en) 2009-06-20
SI2316431T1 (en) 2016-04-29
KR20110005320A (en) 2011-01-17
LU91867I2 (en) 2011-11-08
DE102004016947A1 (en) 2004-10-21
JP2013177404A (en) 2013-09-09
NO20055231D0 (en) 2005-11-07
PE13522013A1 (en) 2013-11-14
ZA200507394B (en) 2007-03-28
ECSP056090A (en) 2006-03-01
RU2012148593A (en) 2014-05-20
TWI332847B (en) 2010-11-11
MY141249A (en) 2010-03-31
EP2769713A1 (en) 2014-08-27
RU2475236C2 (en) 2013-02-20
PE03962005A1 (en) 2005-07-05
IE20040246A1 (en) 2004-12-15
DE202004021680U1 (en) 2010-04-22
US8324283B2 (en) 2012-12-04
IL170888A (en) 2010-06-16
PE02002013A1 (en) 2013-03-09
TNSN05256A1 (en) 2007-07-10
GR20040100121A (en) 2004-12-17
ES2556947T3 (en) 2016-01-21
AT414508T (en) 2008-12-15
HUE028247T2 (en) 2016-12-28
CA2521325C (en) 2010-09-14
NO335120B1 (en) 2014-09-22
CY1110260T1 (en) 2014-04-09
CA2707750A1 (en) 2004-10-21
US20090203798A1 (en) 2009-08-13
ITMI20040682A1 (en) 2004-07-06
NZ592339A (en) 2012-09-28
CY1117071T1 (en) 2017-04-05
US20140011885A1 (en) 2014-01-09
NO20100250L (en) 2006-01-09
RU2010146697A (en) 2012-05-27
HRP20100601A2 (en) 2011-03-31
AU2004228929A1 (en) 2004-10-21
IS8114A (en) 2005-11-01
LU91867I9 (en) 2019-01-03
FR2854073B1 (en) 2008-03-14
AT501681B1 (en) 2012-04-15
NO2011016I2 (en) 2012-08-27
IL197578D0 (en) 2011-07-31
US20190175527A1 (en) 2019-06-13
DK2316431T3 (en) 2016-01-11
CL2004000745A1 (en) 2005-02-11
GR1005052B (en) 2005-11-30
FR2854073A1 (en) 2004-10-29
TW200503784A (en) 2005-02-01
KR101367574B1 (en) 2014-02-25
NZ542622A (en) 2009-01-31
JP2011006461A (en) 2011-01-13
US20110105620A1 (en) 2011-05-05
GB2400318A (en) 2004-10-13
MXPA05010860A (en) 2006-05-25
CA2521325A1 (en) 2004-10-21
RU2010147000A (en) 2012-08-10
NO20055231L (en) 2006-01-09
PL2316431T3 (en) 2016-09-30
BRPI0409250A (en) 2006-03-28
PL1613288T3 (en) 2009-07-31
HRP20050886A2 (en) 2006-11-30
RU2475237C2 (en) 2013-02-20
HRP20100600A2 (en) 2011-03-31
ES2228282B1 (en) 2006-02-16
PE07432009A1 (en) 2009-07-17
HUS1100016I1 (en) 2016-08-29
NZ586280A (en) 2011-12-22
EP2316431A1 (en) 2011-05-04
EP2316431B1 (en) 2015-09-30
JP5495467B2 (en) 2014-05-21
DK1613288T3 (en) 2009-03-23
AT504853A2 (en) 2008-08-15
AR043987A1 (en) 2005-08-17
AR078782A2 (en) 2011-11-30
AR078781A2 (en) 2011-11-30
HK1091114A1 (en) 2009-06-26
WO2004089341A1 (en) 2004-10-21
NO2011016I1 (en) 2011-09-19
HK1071685A1 (en) 2006-08-04
BE1015972A5 (en) 2005-12-06
CL2011000450A1 (en) 2011-11-25
LU91867A9 (en)
HRP20100601B1 (en) 2016-12-02
MA27729A1 (en) 2006-01-02
US20140255497A1 (en) 2014-09-11
EP2319502A1 (en) 2011-05-11
IL242037D0 (en) 2015-11-30
SI1613288T1 (en) 2009-04-30
GB2400318B (en) 2005-08-10
SG175449A1 (en) 2011-11-28
DE602004017847D1 (en) 2009-01-02
NO20131287L (en) 2006-01-09
US20080311188A1 (en) 2008-12-18
NO329332B1 (en) 2010-09-27
AU2004228929B2 (en) 2008-02-07
IS2682B (en) 2010-10-15
CN101797241A (en) 2010-08-11
JP5543298B2 (en) 2014-07-09
GB0407819D0 (en) 2004-05-12
CN1767819A (en) 2006-05-03
KR20050121712A (en) 2005-12-27
ES2228282A1 (en) 2005-04-01
CN1767819B (en) 2010-07-28
RU2005134173A (en) 2006-09-10
CN101797241B (en) 2013-03-27
EP1613288B1 (en) 2008-11-19
DE122011100047I1 (en) 2011-12-15
HRP20050886B1 (en) 2011-01-31
EP1613288A1 (en) 2006-01-11
NO334116B1 (en) 2013-12-16
IS8885A (en) 2010-02-25
KR20120101148A (en) 2012-09-12
ES2320767T3 (en) 2009-05-28
HK1155647A1 (en) 2016-03-24
EP2008650A3 (en) 2011-04-27
RU2009105403A (en) 2010-08-27
EP2008650A2 (en) 2008-12-31
AT501681A1 (en) 2006-10-15
US20130108675A1 (en) 2013-05-02
JP2004307506A (en) 2004-11-04
US20060275357A1 (en) 2006-12-07
US20170290787A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
US20080110792A1 (en) Methods for administering weight loss medications
HN2003000215A (en) Glicocido novel thiophene, processes for the preparation thereof, medicaments containing these compounds and the use thereof.
BR0206752A (en) pharmaceutical Formulation
ES2146300T3 (en) Use of anthelmintic compositions for the treatment of infections caused by Anoplocephala perfoliata in horses.
GT200200138A (en) Vaccination with a single dose Mycoplasma hyopneumoniae
CU23515A3 (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
CR10442A (en) Lyophilized formulations of therapeutic peptibody
UY27921A1 (en) Substituted hydroxamic acids thienyl and their use to treat diseases associated with enzyme activity of histone deacetylase
CO4761054A1 (en) Formula extended release venlafaxine hydrochloride
TW200510375A (en) New compounds
CL2008000058A1 (en) Formulation comprising an anti-IL13 antibody, a cryoprotective, and a buffer solution; pharmaceutical composition comprising the same; method of treating a disorder related to IL13; and dosage forms that they comprise.
ECSP045238A (en) Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
NO20100250L (en) Pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol, and progress feed for the preparation thereof
CO4900058A1 (en) Combination therapy for the treatment of psychoses
ECSP088681A (en) Drug delivery device
CL2007001638A1 (en) Disposable Absorbent Article wearable comprising an absorbent core and an outer shell, wherein the article includes a fastening system configured to secure the absorbent core to a user, wherein at least part of
AR050418A1 (en) Dosage antibody fixed her
ECSP077241A (en) Tablet formulation containing pramipexole extended release or a pharmaceutically acceptable salt of the same, method for its manufacture and its use
NO20064041L (en) Substituted pyrazoline compounds, their preparation and use as medicaments
AR099567A2 (en) Coated tablet formulation comprising saxagliptin and preparation method
CL2008002207A1 (en) pharmaceutical composition comprising immunosuppressants for improving the effect on the use of an antagonist of interleukin-6 (IL-6) for the treatment of diseases related to IL-6 (div. sol. 896-04).
AR040245A1 (en) Dosage forms and compositions for osmotic delivery of varying dosages of oxycodone
NO329067B1 (en) Gamma-secretase, pharmaceutical compositions comprising the compounds and uses of compounds for the preparation of medicaments
PE05312001A1 (en) Pharmaceutical salts of active substance tramadol and at least one sweetener and the dosage forms containing these salts
CO6680609A2 (en) aqueous composition containing bromhexine

Legal Events

Date Code Title Description
FC Refusal